论文部分内容阅读
近年来随着乳腺癌新辅助化疗研究的深入,该治疗手段已在临床广泛应用。新辅助化疗使不可手术的局部晚期乳腺癌患者获得手术治疗的机会,并且提高具有较大肿瘤体积患者的保乳率,从而明显改善患者的生存质量,但仍有许多问题存在争议。《中国肿瘤临床》2016年第15期“特约综述”栏目中,特邀军事医学科学院附属医院乳腺外科主任黄焰教授对乳腺癌新辅助化疗相关临床研究进行综述,并分享其经验与观点。阅读本文请登录网站www.cjco.cn或关注本刊微信公告号(扫描文章下方二维码)查看。
In recent years, with the deepening of neoadjuvant chemotherapy for breast cancer, the treatment has been widely used in clinical practice. Neoadjuvant chemotherapy may lead to surgical treatment of patients with locally advanced unresectable breast cancer and to improve the rate of breast-conserving in patients with large tumor volume, thus significantly improving patient quality of life. However, there are still many controversial issues. “China Oncology Clinical” 2016 15 “” Special Review "column, invited Professor Huang Yan, director of Breast Surgery Affiliated Hospital of Military Academy of Medical Sciences reviewed the clinical research of neoadjuvant chemotherapy for breast cancer and share their experience and views . Read this article, please visit www.cjco.cn or concerned about the publication of WeChat announcement (scan the article below the two-dimensional code) view.